摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+)-FR66979 | 102409-60-9

中文名称
——
中文别名
——
英文名称
(+)-FR66979
英文别名
[(8R,10S,12S)-6,9-dihydroxy-4-(hydroxymethyl)-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-8-yl]methyl carbamate
(+)-FR66979化学式
CAS
102409-60-9
化学式
C14H17N3O6
mdl
——
分子量
323.305
InChiKey
WUQJQATXUALTBZ-JPJPOWIGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.5
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    147
  • 氢给体数:
    5
  • 氢受体数:
    8

SDS

SDS:6b653c7ce5ce61326475b750c76fc16a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION
    申请人:Stoltz Brian M.
    公开号:US20160096810A1
    公开(公告)日:2016-04-07
    This invention provides enantioenriched N,O-heterocyclic compounds with quaternary stereogenic centers and novel methods of preparing the compounds. Methods include the method for the preparation of a compound of formula (I): comprising treating a compound of formula (II): with a transition metal catalyst under alkylation conditions.
    这项发明提供了含有季碳立体中心的手性富集的N,O-杂环化合物以及制备这些化合物的新方法。方法包括制备式(I)化合物的方法:将式(II)化合物在烷基化条件下与过渡属催化剂处理。
  • DNA−DNA Interstrand Cross-Linking by FR66979:  Intermediates in the Activation Cascade
    作者:Manuel M. Paz、Paul B. Hopkins
    DOI:10.1021/ja970350u
    日期:1997.7.1
    mitosene nucleus of reductively activated mitomycins. We report herein evidence substantiating this proposal based upon study of the reductive activation chemistry of 1 and 2 using thiols and iron(II) in the absence and presence of DNA. Prolonged exposure of reductively activated 1 to sodium borohydride afforded the dihydroindole 11, presumably through trapping of the iminium ion precursor (16). Kinetics
    抗肿瘤抗生素 FR66979 (1)、FR900482 (2) 和 FK973 (3) 在结构和生物活性上与 DNA 交联抗肿瘤抗生素丝裂霉素 C (4) 相似。已提出 1-3 的细胞毒性作用是由于 N-O 键的连续生物还原裂解和由此暴露的胺和酮功能的缩合而产生的吲哚(例如 9),其结构类似于丝裂烯核还原活化丝裂霉素。我们在此报告了基于在 DNA 不存在和存在的情况下使用醇和 (II) 对 1 和 2 的还原活化化学的研究证实这一提议的证据。将还原活化的 1 长时间暴露于硼氢化钠,得到二氢吲哚 11,推测是通过捕获亚胺离子前体 (16)。
  • Covalent Structure of the DNA-DNA Interstrand Cross-Link Formed by Reductively Activated FR66979 in Synthetic DNA Duplexes
    作者:Huifang Huang、Tom K. Pratum、Paul B. Hopkins
    DOI:10.1021/ja00086a002
    日期:1994.4
    The lesion responsible for the dG-to-dG, DNA-DNA interstrand cross-link formed at the duplex dinucleotide sequence 5'-d(CG) by reductively activated FR66979 (2) was isolated from the cross-linked synthetic oligonucleotide duplex [5'-d(TATACGTATA)](2). The lesion and a peracetylated derivative of this substance were studied by mass, UV, and H-1 NMR (2D PS COSY and 1D NOE) spectroscopies. The data overwhelmingly support the proposal that this lesion possesses the mitosene-like structure 8, the analog of the lesion 5a formed in DNA by reductively activated mitomycin C. This finding offers in vitro support for the proposal of in vivo bioreductive activation of these substances as the prelude to DNA-DNA interstrand cross-linking.
查看更多

同类化合物

氨甲酸(1aS,8R,9aS)-5-甲酰基-7,9-二羟基-3,9-环氧-2,3,8,9,9a,9b-六氢-1H-吖丙因并[2,3-c][1]苯并吖辛因-8-基甲基酯 1-乙酰基-7,9-二(乙酰氧基)-8-(((氨基羰基)氧基)甲基)-1,1a,2,8,9,9a-六氢-3,9-环氧-3H-氮丙啶并(2,3-c)(1)苯并氮杂环辛四烯-5-甲醛 (1aS,3S,8R,9S,9aS)-1-乙酰基-7,9-二(乙酰氧基)-8-(((氨基羰基)氧基)甲基)-1,1a,2,8,9,9a-六氢-3,9-环氧-3H-氮丙啶并(2,3-c)苯并氮杂环辛四烯-5-甲醛 Antibiotic FR 900482 6-(4-methyl-thiazol-2-yl)-dibenzo[d,f][1,3]diazepine-5,7-diol 11-acetyl-4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate 1-tert-butyl-2,1-benzisoxazoline 1-methyl-3-morpholin-4-yl-1,3-dihydro-benzo[c]isoxazole 7-Ethyl-3-methyl-1,3-dihydro-2,1-benzoxazole methyl (4aR,10aS,11aS,11bS)-4,4a,10,10a,11,11b-hexahydro-11-(tert-butyloxycarbonyl)-4a-formyl-5-hydroxy-2,2-dimethyl-9,11b-epoxyazirino[2,3-c]-1,3-dioxino[4,5-e][1]benzazocine-7-carboxylate methyl (1aS,8R,9S,9aS)-1,1a,2,8,9,9a-hexahydro-1-(tert-butyloxycarbonyl)-8-formyl-7,9-dihydroxy-8-(hydroxymethyl)-3,9-epoxy-3H-azirino[2,3-c][1]benzazocin-5-carboxylate (1aS,3R,8R,9R,9aS)-dimethyl ester 8-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,1a,2,8,9,9a-hexahydro-9-hydroxy-7-(methoxymethoxy)-3,9-epoxy-3H-azirino[2,3-c][1]benzazocine-1,5-dicarboxylic acid methyl (4R,6R)-2-(2-methoxypropan-2-yloxy)-7-oxo-10-phenylmethoxy-5-oxa-2-azatricyclo[7.4.0.04,6]trideca-1(9),10,12-triene-12-carboxylate FR66979 (+)-FR900482 [(1S,6R,15S,16R)-15-azido-10-(hydroxymethyl)-3-oxo-8-phenylmethoxy-2,4,17-trioxa-13-azatetracyclo[11.3.1.01,6.07,12]heptadeca-7(12),8,10-trien-16-yl] methanesulfonate 4-hydroxylamino-1,1,2,2,9,9,10,10-octafluoro[2.2]paracyclophane 4',7-dichlorospiro[1H-2,1-benzoxazole-3,3'-1H-pyrrole]-2'-one 11-O'-tert-butyl 4-O'-methyl (4S,9'R,10'S,12'S)-6',9'-dihydroxy-2-oxospiro[1,3-dioxolane-4,8'-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-triene]-4',11'-dicarboxylate 1-tert-Butyl-2,1-benzisoxazolin-3-ol (+)-FR900482 7-epi-(+)-FR900482 11-O-tert-butyl 4-O-methyl (8S,9R,10S,12S)-6,9-dihydroxy-8-(hydroxymethyl)-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-triene-4,11-dicarboxylate methyl (4R,6R,7S)-2-hydroxy-10-phenylmethoxy-7-tri(propan-2-yl)silyloxy-5-oxa-2-azatricyclo[7.4.0.04,6]trideca-1(9),10,12-triene-12-carboxylate (1,4-dihydroxy-3-iminoquinoxalin-2-ylidene)-nitrosomethanamine 2-(1H-2,1-benzoxazol-3-ylidene)-5-methylimidazole-4-carboxylic acid 4-Hydroxy-1-oxo-2,3-dihydro-1,2,4-benzotriazin-1-ium-3-amine N-[1H-2,1-benzoxazol-3-ylidene(nitroso)methyl]-3-chloro-4-fluoroaniline 4-hydroxy-6-methyl-3H-1,2,4-benzotriazin-3-amine 1,4-dihydroxy-3-imino-2H-quinoxaline-2,5,8-triamine N-(11-amino-5-tricyclo[8.2.2.24,7]hexadeca-1(12),4,6,10,13,15-hexaenyl)hydroxylamine;ethane 2-[[4-(3-chlorophenyl)-1H-2,1-benzoxazol-3-ylidene]methyl]-5-methyl-N-[2-(triazol-1-yl)ethyl]-1H-pyrrole-3-carboxamide 1-(1H-2,1-benzoxazol-3-ylidene)-N-[(2-methylphenyl)methyl]-1-nitrosomethanamine 6-Methyl-5,7-dihydroxy-6,7-dihydro-5H-dibenzo<1,3>diazepin 6-ethyl-dibenzo[d,f][1,3]diazepine-5,7-diol 2-(3H-Benzo[c]isoxazol-1-ylmethyl)-malononitrile 1,4-di-N-oxide-3-amino-2-imidazolequinoxaline. (1S,6R,15S,17S)-10-(dimethoxymethyl)-8-phenylmethoxy-2,4,18-trioxa-13,16-diazapentacyclo[11.4.1.01,6.07,12.015,17]octadeca-7(12),8,10-trien-3-one (+)-FR66979 4-formyl-6,9-dihydroxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate 6,9-dihydroxy-4-hydroxymethyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-8-ylmethyl carbamate methyl N-[(1-hydroxy-4-oxido-3,4-dihydroquinoxalin-4-ium-2-ylidene)methylimino]carbamate 1,4-Dihydroxy-2,3-dihydroquinoxaline methyl N-[(1,4-dihydroxy-2,3-dihydroquinoxalin-2-yl)methylideneamino]carbamate